Adjuvant Treatment for HR+/HER2-, Node-Positive, High-Risk eBC: 4-Year Results From the monarchE Study

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

AdventHealth

Videos
Third Annual Pulmonary Hypertension
Pancreas Updates 2024
Endoscopic Weight Loss Center Webinar
Orlando Live! Endoscopy 2024
International Brain Health Symposium 2024
Oncology
Events

Playback speed

10 seconds

Adjuvant Treatment for HR+/HER2-, Node-Positive, High-Risk eBC: 4-Year Results From the monarchE Study

By SABCS 2022 Conference Coverage FEATURING Wassim Mchayleh

304 views

February 7, 2023

Comments 0

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma With Mul…

Feat. R. Alter, A. Rezazadeh

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss

Oncology

New

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

236 views

ESMO 2024 Summary: Key Trial Results in Advanced Bladder Cancer Trea…

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

154 views

Developmental Therapeutics Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

533 views

Bladder Cancer Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

1.4K views

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.9K views

FDA Approval of Gemcitabine-Cisplatin + Nivo as 1L Therapy for Advan…

AdventHealth

G. Sonpavde

274 views

ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Carcino…

Insights from 2024 ASCO® GU Annual Meeting

G. Sonpavde

415 views

ESMO23 Highlights in Urothelial Carcinoma

Insights from 2023 ESMO Annual Meeting

G. Sonpavde, B. McGregor

243 views

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Insights from 2023 ESMO Annual Meeting

G. Sonpavde

853 views

ASCO® 2023 Summary: "Key Bladder Cancer/Urothelial Carcinoma Updates"

Insights from 2023 ASCO® Annual Meeting

G. Sonpavde

376 views

Update on the FDA Accelerated Approval of Enfortumab Vedotin + Pembr…

AdventHealth

G. Sonpavde

902 views

ESMO 2022 on the 4-Factor Model to Predict Response and Survival Ben…

ESMO 2022 Conference Coverage

G. Sonpavde

134 views

ESMO 2022: Key Bladder Cancer/Urothelial Carcinoma Presentations

ESMO 2022 Conference Coverage

G. Sonpavde

810 views

Adjuvant Treatment for HR+/HER2-, Node-Positive, High-Risk eBC: 4-Ye…

SABCS 2022 Conference Coverage

W. Mchayleh

304 views